Skip to Content
Upcoming Webinar

RET Fusion-Positive Metastatic NSCLC: the Role of Pralsetinib and an Update from the ARROW Clinical Trial

Date: December 3, 2025 | 2:00 PM
When: Wednesday, December 3 | 2 p.m. EST
Presenters:
Cynthia Villarimo-Schauer, PhD | Rigel Medical Affairs

RET fusion–positive metastatic NSCLC is a small but important patient group — and staying current on the science behind RET alterations and targeted options like pralsetinib is key to making confident treatment decisions.

In this session, Cynthia Villarimo-Schauer, PhD, takes a clear, practical look at the biology, guidelines, and data shaping care today, including:

  • RET biology + prevalence in NSCLC and why it matters
  • Current NCCN guidance and the role of biomarker testing
  • Efficacy and safety findings for pralsetinib from the Phase II ARROW trial

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.